Neomorph Raises $100M Series B to Advance Molecular Glue Degrader Therapies for Undruggable Targets
Biology doesn’t usually negotiate. It runs its code, repeats its patterns, and dares anyone to interrupt. Neomorph walked in, read the room, and started rewriting outcomes without raising its voice. Out in San Diego, Philip Chamberlain, CEO, and crew have been quietly engineering a different conversation with disease. Not louder. Just smarter. Molecular glue degraders sound like something cooked up in a comic book lab, but the reality is cleaner and colder. Instead of blocking a bad actor, Neomorph is telling the cell to take out its own trash. No debate, no negotiation, just a targeted escort to the exit.
That’s the backdrop for a $100M Series B led by Deerfield Management, with Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, and Binney Street Capital stepping in like they’ve seen this movie before and know how it ends. When the same lead investor doubles down from Series A to Series B, that’s not optimism. That’s conviction with receipts.
Neomorph has now pulled in $209M total, and the timing is no accident. NEO-811 just entered the clinic, dosing its first patient in Feb 2026. First-in-human always carries a certain gravity. It’s where theory meets consequence, where elegant science either translates or gets humbled. The trial is already in motion, targeting clear cell renal cell carcinoma, and every data point from here starts shaping the next decade of this category.
What makes this story stick isn’t just the capital or the clinical milestone. It’s the pattern. Start with a platform that expands the “undruggable” universe. Stack partnerships with Novo Nordisk, Biogen, and AbbVie that stretch across cardiometabolic, neuro, immunology, and oncology. Then bring your own assets into the clinic so you’re not just licensing potential, you’re proving it.
That’s how you build leverage in biotech. Not by chasing headlines, but by designing a system where every experiment compounds. The name Neomorph does a little storytelling on its own. New form. New function. New outcomes. In a market where most therapies are still trying to outmuscle disease, this approach is more surgical, almost philosophical. Don’t fight the protein. Redefine its fate.
